Comparison of Two Antibiotic Regimens (piperacillin Plus Amikacin Versus Ceftazidime Plus Amikacin) As Empiric Therapy for Febrile Neutropenic Patients with Cancer

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 1992 Dec 1

PMID 1482151

Citations 5

Authors

J Feliu

A Artal

M Gonzalez Baron

A Berrocal

I Chacon

M L Garcia de Paredes

E Espinosa

A Ordonez

P Zamora

J M Montero

Affiliations

Soon will be listed here.

Abstract

A total of 170 febrile episodes in neutropenic patients with cancer were randomly assigned to be treated with piperacillin-amikacin or ceftazidime-amikacin. The overall response rates were similar in both groups (68 and 65%, respectively). Response rates for clinically or microbiologically documented episodes were 54.5% for piperacillin-amikacin and 58.8% for ceftazidime-amikacin. Response rates for gram-negative bacillary infections were 65 and 73%, respectively. There was also no difference for gram-positive infections (31 and 50%, respectively). The toxicities were also comparable and consisted of skin rashes, hypokalemia, and diarrhea. Vancomycin was added if the fever persisted 72 h after the beginning of therapy; it increased the response rates to 94% when used with piperacillin-amikacin and 92% when used with ceftazidime plus amikacin. Our results suggest that the combinations show similar global efficacies in the treatment of febrile episodes in cancer patients.

Citing Articles

Piperacillin-tazobactum plus amikacin versus ceftazidime plus amikacin as empirical therapy for Fever in neutropenic patients with hematological malignancies.

Ghalaut P, Chaudhary U, Ghalaut V, Dhingra A, Dixit G, Aggarwal S Indian J Hematol Blood Transfus. 2012; 27(3):131-5.

PMID: 22942562 PMC: 3155712. DOI: 10.1007/s12288-011-0076-0.

Infectious complications in patients with hematological malignancies consulted by the Infectious Diseases team: a retrospective cohort study (1997-2001).

Guven G, Uzun O, Cakir B, Akova M, Unal S Support Care Cancer. 2005; 14(1):52-5.

PMID: 15947955 DOI: 10.1007/s00520-005-0836-1.

Piperacillin-tazobactam and netilmicin as a safe and efficacious empirical treatment of febrile neutropenic children.

Le Guyader N, Auvrignon A, Vu-Thien H, Portier E, Tabone M, Leverger G Support Care Cancer. 2004; 12(10):720-4.

PMID: 15138864 DOI: 10.1007/s00520-004-0641-2.

[Febrile neutropenia: practical aspects].

Harten P, Seyfarth B, Schmitz N Med Klin (Munich). 1998; 93(10):598-611.

PMID: 9849051 DOI: 10.1007/BF03042675.

Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Rains C, Bryson H, Peters D Drugs. 1995; 49(4):577-617.

PMID: 7789291 DOI: 10.2165/00003495-199549040-00008.

References

Casali A, Ameglio F, Gionfra T, Tonachella R, Paoletti G, Gallo Curcio C . Amikacin plus ceftazidime versus amikacin plus piperacillin versus amikacin plus aztreonam in infections in neoplastic patients with granulocytopenia. Chemioterapia. 1987; 6(6):440-4. View

Winston D, Murphy W, Young L, HEWITT W . Piperacillin therapy for serious bacterial infections. Am J Med. 1980; 69(2):255-61. DOI: 10.1016/0002-9343(80)90386-1. View

Bodey G, Alvarez M, Jones P, Rolston K, Steelhammer L, Fainstein V . Imipenem-cilastatin as initial therapy for febrile cancer patients. Antimicrob Agents Chemother. 1986; 30(2):211-4. PMC: 180520. DOI: 10.1128/AAC.30.2.211. View

Yost R, Ramphal R . Ceftazidime review. Drug Intell Clin Pharm. 1985; 19(7-8):509-13. DOI: 10.1177/106002808501900701. View

Meunier F, Zinner S, Gaya H, Calandra T, Viscoli C, Klastersky J . Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of.... Antimicrob Agents Chemother. 1991; 35(5):873-8. PMC: 245122. DOI: 10.1128/AAC.35.5.873. View

Gardembas-Pain M, Desablens B, Sensebe L, Lamy T, Ghandour C, Boasson M . Home treatment of febrile neutropenia: an empirical oral antibiotic regimen. Ann Oncol. 1991; 2(7):485-7. DOI: 10.1093/oxfordjournals.annonc.a057996. View

Hughes W, Armstrong D, Bodey G, Feld R, Mandell G, Meyers J . From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis. 1990; 161(3):381-96. DOI: 10.1093/infdis/161.3.381. View

Bodey G, Fainstein V, Elting L, Anaissie E, Rolston K, Khardori N . Beta-lactam regimens for the febrile neutropenic patient. Cancer. 1990; 65(1):9-16. DOI: 10.1002/1097-0142(19900101)65:1<9::aid-cncr2820650105>3.0.co;2-c. View

Stuart C, Pate C, Peters E . Prevalence of acanthosis nigricans in an unselected population. Am J Med. 1989; 87(3):269-72. DOI: 10.1016/s0002-9343(89)80149-4. View

10.

Gucalp R, Lia S, McKitrick J, Wiernik P . Cefoperazone plus tobramycin versus ticarcillin plus tobramycin in febrile granulocytopenic cancer patients. Am J Med. 1988; 85(1A):31-5. DOI: 10.1016/0002-9343(88)90172-6. View

11.

Shenep J, Hughes W, Roberson P, Blankenship K, Baker Jr D, Meyer W . Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. N Engl J Med. 1988; 319(16):1053-8. DOI: 10.1056/NEJM198810203191604. View

12.

Fenu S, Raccah R, Santilli S, Micozzi A, Girmena C, Martino P . Treatment of febrile episodes in neutropenic leukemic patients with the antibiotic combinations piperacillin or ceftazidime plus amikacin: results of a randomized study. Chemioterapia. 1988; 7(5):323-6. View

13.

OBrien A, Fenelon L, ODwyer R, McCann S, Daly P . A comparative study of latamoxef disodium and gentamicin versus piperacillin and gentamicin in febrile granulocytopenic patients. Br J Clin Pract. 1988; 42(2):56-60. View

14.

Rubin M, Hathorn J, Marshall D, Gress J, Steinberg S, Pizzo P . Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med. 1988; 108(1):30-5. DOI: 10.7326/0003-4819-108-1-30. View

15.

Pizzo P, Hathorn J, Hiemenz J, Browne M, Commers J, Cotton D . A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med. 1986; 315(9):552-8. DOI: 10.1056/NEJM198608283150905. View

16.

Young L . Empirical antimicrobial therapy in the neutropenic host. N Engl J Med. 1986; 315(9):580-1. DOI: 10.1056/NEJM198608283150910. View

17.

Feld R, Louie T, Mandell L, Bow E, Robson H, Chow A . A multicenter comparative trial of tobramycin and ticarcillin vs moxalactam and ticarcillin in febrile neutropenic patients. Arch Intern Med. 1985; 145(6):1083-8. View

18.

de Jongh C, Wade J, Schimpff S, Newman K, Finley R, Salvatore P . Empiric antibiotic therapy for suspected infection in granulocytopenic cancer patients: a comparison between the combination of moxalactam plus amikacin and ticarcillin plus amikacin. Am J Med. 1982; 73(1):89-96. DOI: 10.1016/0002-9343(82)90935-4. View

19.

Klastersky J, Glauser M, Schimpff S, Zinner S, Gaya H . Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients. Antimicrob Agents Chemother. 1986; 29(2):263-70. PMC: 176388. DOI: 10.1128/AAC.29.2.263. View